Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$8.75
-0.12 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $282.8M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
36.5x
↑EV/EBITDA
16.7x
↑ROE
4.4%
↑Gross Margin
8.2%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.5%
FCF CAGR
-2.0%
FCF margin
2.7%
FCF / Net income
2.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.38B · net income $133.8M · FCF $282.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.38B | $10.38B | $10.05B | $10.39B | $9.64B |
| Net Income | $133.8M | $133.8M | $213.3M | $292.2M | $264.5M |
| EBITDA | $273.1M | $273.1M | $378.9M | $480.8M | $454.0M |
| EPS | 0.23 | 0.23 | 0.37 | 0.50 | 0.46 |
| Gross Margin | 8.2% | 8.2% | 8.6% | 9.6% | 9.5% |
| Operating Margin | 2.8% | 2.8% | 3.2% | 4.3% | 3.9% |
| Net Margin | 1.3% | 1.3% | 2.1% | 2.8% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.31 | 0.37 | 0.52 |
| Current Ratio | 1.66 | 1.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $282.8M | $282.8M | $107.4M | $309.5M | $300.9M |
| Returns | |||||
| ROE | 4.4% | 4.4% | 7.4% | 10.6% | 10.8% |
| Valuation | |||||
| P/E | 36.46 | 36.46 | 18.87 | 15.60 | 14.10 |
| EV/EBITDA | 16.73 | 16.73 | 10.09 | 8.87 | 8.40 |
| P/B | 1.68 | 1.68 | 1.40 | 1.66 | 1.52 |
| Growth & Yield | |||||
| Revenue Growth | 3.3% | 3.3% | -3.3% | 7.8% | — |
| EPS Growth | -37.2% | -37.2% | -27.0% | 10.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
49.8%
EPS terminal req.
$0.78
Spread vs growth
-87.1%
5Y implied EPS CAGR
32.4%
EPS terminal req.
$0.94
Spread vs growth
-69.7%
10Y implied EPS CAGR
20.7%
EPS terminal req.
$1.51
Spread vs growth
-57.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.8%
Start / end P/E
20.2x → 37.9x
EPS bridge
0.37 → 0.23
Residual
-32.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.